Current Report Filing (8-k)
August 18 2017 - 2:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 16, 2017
DOUGHERTY’S
PHARMACY, INC.
(Exact name of registrant as specified in
its charter)
Commission File Number:
000-27945
Delaware
|
75-2900905
|
(State or other jurisdiction
|
(IRS Employer
|
of incorporation)
|
Identification No.)
|
5924 ROYAL LANE, SUITE 250
DALLAS, TEXAS 75230
(Address of principal executive offices
and Zip Code)
Registrant’s telephone number, including
area code:
972-250-0945
N/A
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR §240. 12b-2).
Emerging growth company [_]
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
|
On August 16, 2017, the Board of Directors
of Dougherty’s Pharmacy, Inc. (the “
Company
”) appointed Mr. Troy Phillips as a Class A Director.
Mr. Phillips has been the Chairman of the Board and CEO of Glast, Phillips & Murray, P.C., a law firm, since 1992. Mr. Phillips
specializes in business litigation, devoting a substantial portion of his practice to prebankruptcy strategies, loan workouts,
purchase of assets from bankruptcy estates, and refinancings. He also has extensive experience in corporate reorganizations, leveraged
buy-outs and avoidance of prebankruptcy transfers. Mr. Phillips has practiced law privately since 1974. Mr. Phillips received his
bachelor's degree from North Texas State University and his law degree from the University of Texas at Austin in 1974, where he
was a member of the Order of Barristers and the University of Texas State Champion Moot Court Team. He is a member of the College
of the State Bar of Texas, and is an occasional speaker at legal and professional seminars as well as an author on business bankruptcy
law. Mr. Phillips has been admitted to practice and has handled cases before Courts in the State of Texas, the Northern and Eastern
Federal Districts of Texas, the Fifth Circuit Court of Appeals, and the United States Supreme Court.
On August 18, 2017, the Company issued the
attached press release announcing the appointment of Mr. Phillips to the Board of Directors. A copy of the Company’s
press release is attached hereto as Exhibit 99.1.
Item 9.01
|
Financial Statements and Exhibits
|
(d) The following
exhibit is furnished herewith:
99.1 Press
Release Dated August 18, 2017.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: August 18, 2017
|
Dougherty’s Pharmacy, Inc .
|
|
|
|
By:
|
/s/ Mark S. Heil
|
|
|
Mark S. Heil
President and Chief Financial Officer (Duly Authorized Principal
Executive Officer and Principal Financial Officer)
|